These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16996857)

  • 1. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.
    Zhang Z; Foster JK; Kolm P; Jurkovitz CT; Parker KM; Murrah NV; Anderson GT; Douglas JS; Weintraub WS
    Am Heart J; 2006 Oct; 152(4):770-6. PubMed ID: 16996857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial.
    Weintraub WS; Foster J; Culler SD; Becker ER; Parker K; Zhang Z; Kolm P; Douglas JS;
    J Invasive Cardiol; 2004 May; 16(5):257-9. PubMed ID: 15152132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary stent restenosis in patients treated with cilostazol.
    Douglas JS; Holmes DR; Kereiakes DJ; Grines CL; Block E; Ghazzal ZM; Morris DC; Liberman H; Parker K; Jurkovitz C; Murrah N; Foster J; Hyde P; Mancini GB; Weintraub WS;
    Circulation; 2005 Nov; 112(18):2826-32. PubMed ID: 16246948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Jang JS; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Kim DK; Seol SH; Kim DI; Cho KI; Kim BH; Park YH; Je HG; Jeong YH; Kim WJ; Lee JY; Lee SW
    Cardiology; 2012; 122(3):133-43. PubMed ID: 22832424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
    Tamhane U; Meier P; Chetcuti S; Chen KY; Rha SW; Grossman MP; Gurm H
    EuroIntervention; 2009 Aug; 5(3):384-93. PubMed ID: 19736165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.
    Douglas JS; Weintraub WS; Holmes D
    Clin Cardiol; 2003 Oct; 26(10):451-4. PubMed ID: 14579914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent.
    Chen YD; Lu YL; Jin ZN; Yuan F; Lü SZ
    Chin Med J (Engl); 2006 Mar; 119(5):360-6. PubMed ID: 16542577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).
    Lee SW; Ahn JM; Han S; Park GM; Cho YR; Lee WS; Jang JY; Kwon CH; Lee JY; Kim WJ; Kang SJ; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2013 Nov; 112(9):1328-34. PubMed ID: 23890573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
    Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
    Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
    Inoue T; Uchida T; Sakuma M; Imoto Y; Ozeki Y; Ozaki Y; Hikichi Y; Node K
    J Am Coll Cardiol; 2004 Oct; 44(7):1408-14. PubMed ID: 15464320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS).
    Yamagami H; Sakai N; Matsumaru Y; Sakai C; Kai Y; Sugiu K; Fujinaka T; Matsumoto Y; Miyachi S; Yoshimura S; Hyogo T; Kuwayama N; Hyodo A
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):193-9. PubMed ID: 20851621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.
    Jennings DL; Kalus JS
    J Clin Pharmacol; 2010 Apr; 50(4):415-21. PubMed ID: 20081227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
    Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
    Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.